Ad Header

PharmaLive

Slogan

The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

Indivior slashes 2018 revenue outlook for Sublocade

Indivior Plc slashed full-year 2018 revenue expectation for the injectable opioid addiction drug Sublocade, sending the company’s shares tumbling more than 16 percent.

Read More »

Senate Overwhelmingly Passes Bill to Address Prescription Opioids

The U.S. Senate overwhelmingly supported a new bill aimed at opioid abuse and other addictive drugs.

Read More »

FDA Grants Breakthrough Therapy Designation for Concentric Analgesics’ CA-008 in Post-Surgical Pain

Concentric Analgesics Inc. announced today that the clinical-stage biopharmaceutical company received Breakthrough Therapy designation from the U.S. Food and Drug Administration for CA-008 in post-surgical pain.

Read More »

Orexo soars after winning opioid drug appeal against Teva

A U.S. appeals court revived Swedish pharmaceutical company Orexo AB’s lawsuit accusing a unit of Israel’s Teva Pharmaceutical Industries Ltd. of infringing a patent for the opioid addiction drug Zubsolv.

Read More »

Consort, Opiant to develop nasal spray for opioid overdose treatment

Britain’s Consort Medical Plc agreed to develop a nasal spray for treating opioid overdoses with specialty pharmaceutical company Opiant Pharmaceuticals Inc.

Read More »

Emergent BioSolutions to buy Narcan maker Adapt Pharma

Emergent BioSolutions will buy privately held Adapt Pharma, beefing up its portfolio with Narcan, the only FDA-approved needle-free emergency opioid overdose treatment.

Read More »

U.S. joins lawsuits against Indivior, Reckitt over drug Suboxone

The U.S. Justice Department joined several whistleblower lawsuits against Indivior and Reckitt Benckiser Group, alleging that the drugmakers improperly marketed the opioid addiction treatment Suboxone.

Read More »

FDA Issues New Draft Guidance to Promote Development of Medications to Treat Opioid Use Disorder

The U.S. Food and Drug Administration issued a new draft guidance for the development of novel medicines aimed at the treatment of opioid use disorder.

Read More »

Indivior: U.S. court rules against generic rival’s appeal

Indivior Plc notched a legal victory after a U.S. court reaffirmed that a generic rival could not re-launch cheaper versions of the British drugmaker’s best-selling opioid addiction treatment in the United States.

Read More »

U.S. court expedites Indivior rival’s appeal to re-launch generic drug

Indivior said a U.S. court expedited a generic rival’s appeal against a preliminary injunction that blocked the sale of a copycat version of the British drugmaker’s blockbuster opioid addiction treatment.

Read More »

Ad Right Top

MedAdNews

Extensive pharmaceutical business and marketing intelligence. For back issues, please contact MDAD@kmpsgroup.com.

June 2019 Focus: Payer access, biotech/biopharma, DTC, rare diseases, and more!

Subscribe

Ad Right Bottom